Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
30 October 2018
9 month interim report
- 07.00 CET Press release
- No conference call
IR events›
| Date | Event details |
|---|---|
| 13 November 2018 | Barclays R&D call with Dhaval Patel, CSO1/1 meetings |
| 14 November 2018 | UBS European Conference 2018, London1/1 meetings |
| 15 November 2018 | 2018 Jefferies Global Healthcare Conference, London1/1 meetings |
Latest News
- 18 Oct 2018 UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis
- 18 Oct 2018 UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase
- 18 Oct 2018 The impact of fragility fractures due to osteoporosis is being ignored
Outlook 2018
2018 revenue reporting to reach approximately
€ 4.5-4.6 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of
€ 1.3-1.4 billion
Core earnings per share are therefore expected in the range of
€ 4.30-4.70
based on an average of
188 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
